Leucine amplifies the effects of metformin on insulin sensitivity and glycemic control in diet-induced obese mice

Abstract

Background and objectiveThe Sirt1/AMPK signaling pathway is a key sensor of energy status and regulates glucose and lipid metabolism. Leucine (Leu) activates Sirt1 by lowering its Km for NAD+ and potentiates other sirtuin/AMPK-activators, resulting in improvement of insulin sensitivity. Since metformin (Met) converges on this pathway, we hypothesized that leucine would amplify its gluco-regulatory effects. Materials and methodsThe effects of Leu (24g/kg diet)+Met (0.05–0.5g/kg diet) combinations were compared to standard therapeutic Met (1.5g/kg diet; ~300mg/kg BW) on glycemic control in high fat diet induced insulin resistant mice for 6weeks. The effects of Leu on Met stimulation of Sirt1 and AMPK activities were further evaluated in adipocytes. ResultsSub-therapeutic levels of Met combined with Leu resulted in increases in Sirt1 activity and in tissue P-AMPK/AMPK ratio and corresponding dose-responsive improvements in fasting and post-prandial glucose, in glucose response to an insulin tolerance test and in the area under the curve in glucose tolerance tests. Changes were evident within 7days of treatment and sustained throughout the 6-week study duration. The Leu+Met (0.25g/kg)-combinations produced a comparable effect to a standard therapeutic Met dose, while the Leu+Met (0.5g/kg diet) resulted in greater improvements. Since resveratrol also synergizes with leucine to augment sirtuin signaling and insulin sensitivity, we tested the addition of resveratrol to Leu–Met and found no additional benefit. ConclusionThese data demonstrate that adding Leu to Met enables a dose reduction of 66% with improved efficacy and of 83% with comparable efficacy to standard metformin in diet-induced obese mice, and addition of resveratrol does not provide further benefit.